Vanderbilt research finds that GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.

Christianne Roumie, MD, MPH, has been named director of the Vanderbilt University School of Medicine Master of Public Health program, a two-year interdisciplinary program accredited by the Council on Education for Public Health.

An observational study using medical record information from nearly 50,000 U.S. military veterans sheds new light on which drugs are best for patients with Type 2 diabetes and one of its common complications, kidney disease.

Vanderbilt University Medical Center has been awarded a five-year federal grant to train investigators in Learning Healthcare Systems research, aimed at improving patient outcomes and the community’s overall health.

Vanderbilt University Medical Center (VUMC) has established a new career development program for scientists in implementation research. The goal is to speed the uptake and translation of scientific discoveries into routine clinical practice.

In an observational study by researchers at Vanderbilt University Medical Center, adults with type 2 diabetes who take insulin in addition to the recommended first-line drug therapy, metformin, had a 30 percent higher risk of heart attack, stroke or death when compared to similar patients who instead augment their metformin regimen with a sulfonylurea.

Patients prescribed the diabetes drug metformin have a lower risk for heart attack, stroke and death than patients taking sulfonylurea drugs.